It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin to Start US PI Study on IDO Inhibitor-Bavencio Combo
November 5, 2018
- 8 Major Drug Makers See Flat Sales in 1st Half; Overseas Growth Continues to Compensate for Slumping Japan Revenue
November 5, 2018
- Pfizer Files Vyndaqel for Sakigake-Designated Transthyretin Amyloid Cardiomyopathy Indication in Japan
November 5, 2018
- JCR’s Fabrazyme Biosimilar to Enter NHI Price List as Early as November
November 5, 2018
- Takeda Unveils Estimated Net Debt, Goodwill Post Shire Integration
November 2, 2018
- Eisai, Merck to Start Lenvima Commercial Collaboration in Major Markets by March-End
November 2, 2018
- Eisai’s 1st Half Operating Profit Zooms 74% on Lenvima Boon
November 2, 2018
- Ono Plans to File Opdivo for 2nd-Line Esophageal Cancer by March-End
November 2, 2018
- Ono Racks Up 19% Revenue Rise on Positive Opdivo Sales
November 2, 2018
- Ribomic Launches PI/IIa Study of Anti-FGF2 Aptamer in US for AMD
November 2, 2018
- Astellas Investing 30 Billion Yen in R&D, Production Facilities Catering to Multiple Modalities
November 1, 2018
- Japan Needs New Pricing Model for Gene Therapies: Astellas Chief
November 1, 2018
- Astellas Sales Rep Number Now at 2,100; Redundancy Program Gets Underway
November 1, 2018
- Daiichi Sankyo Pushes Back Profit Target in 5-Year Plan, Eyes Intensive Investment in Oncology
November 1, 2018
- Chugai Drops Herceptin Patent Suits against Daiichi Sankyo, Pfizer
November 1, 2018
- Daiichi Sankyo’s Half-Year Revenue Fell 4.8% as Generics Sap Olmesartan Sales
November 1, 2018
- Takeda Unveils Post-Acquisition Executive Team, 2 of 20 Members from Shire
November 1, 2018
- Takeda Sees Flat Sales as Brisk US Revenue Offset by Off-Patent Divestiture
November 1, 2018
- Biogen Japan COO Ajai Sulekh Named as New President
November 1, 2018
- Daiichi Sankyo to Discontinue Development of Intradermal Flu Vaccine
November 1, 2018
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…